Loading news...
Rockwell Medical (RMTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Rockwell Medical (RMTI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--$RMTI announced preliminary unaudited financial results for the three months and twelve months ended December 31, 2025.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical is a viable alternative supplier in the western U.S., serving customers with a reliable supply chain and high-quality products.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical extends its product purchase agreement with one of the largest dialysis providers in the United States through December 31, 2026.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Joe Dawson is a seasoned executive who has extensive operational experience and a strong network in the renal care space.
Rockwell Medical, Inc. ( RMTI ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Heather Hunter - Senior VP & COO Mark Strobeck - President, CEO & Director Jesse Neri - Senior VP & CFO Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Nicholas Sherwood - Maxim Group LLC, Research Division Anthony Vendetti - Maxim Group LLC, Research Division Presentation Operator Good morning, and welcome to Rockwell Medical's Third Quarter 2025 Results Conference Call and Webcast.
Rockwell Medical (RMTI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.05 per share a year ago.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical achieved profitability on an Adjusted EBITDA basis for the third quarter 2025.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Mr. Brown has built a distinguished career leading complex manufacturing and supply chain organizations.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Come visit Rockwell Medical in Booth #316 at ASN Kidney Week 2025 in Houston, TX.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Our team's hard work and dedication are what make Rockwell Medical a leader in our industry and an exceptional place to build a career.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the third quarter ended September 30, 2025 on Wednesday, November 12, 2025.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Heather Hunter was promoted to Chief Operating Officer, having previously served as Chief Corporate Affairs Officer since August 2022.
Rockwell Medical (RMTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rockwell Medical (RMTI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Rockwell Medical (RMTI) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Rockwell Medical, Inc. (NASDAQ:RMTI ) Q2 2025 Earnings Conference Call August 14, 2025 8:00 AM ET Company Participants Heather H. Hunter - Senior VP & Chief Corporate Affairs Officer Jesse Neri - Senior VP & CFO Mark Strobeck - President, CEO & Director Conference Call Participants Jeremy Pearlman - Maxim Group LLC, Research Division Raghuram Selvaraju - H.C.
Rockwell Medical (RMTI) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.01 per share a year ago.